beta

GKOS

Glaukos Corporation

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde

Market Cap: 4.23 Billion

Primary Exchange: NEW YORK STOCK EXCHANGE INC.

Website: http://www.glaukos.com/

Shares Outstanding: 49.5 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.8553933633430424

Sector: Manufacturing

Industry: Surgical and Medical Instrument Manufacturing

Ethical Flags

Longest drawdown: 923 trading days

From: 2021-04-28 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud